ArticleThe New England journal of medicine2021
Avacopan for the Treatment of ANCA-Associated Vasculitis. Reply.
Article in The New England journal of medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- IgA nephropathy new therapies: from data in adults to application in children.Pediatric nephrology (Berlin, Germany) · 2026Review
- Neutrophil-microglia interaction drives motor dysfunction in a neuromyelitis optica model induced by subarachnoid AQP4-IgG.The Journal of clinical investigation · 2026Article
- Integrative proteogenomic characterization reveals therapeutic targets in poorly differentiated and anaplastic thyroid cancers.Nature communications · 2025Article
- Why Is C5a Inflammatory Complement Inhibition Not Enough to Improve C3 Glomerulopathy?Journal of the American Society of Nephrology : JASN · 2025Article
- An Insidious Case of Rapidly Progressive Glomerulonephritis Secondary to Pauci-Immune Crescentic Glomerulonephritis.Cureus · 2024Article
- DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dysfunction-associated steatotic liver disease.Clinical and molecular hepatology · 2024Article
- Immune profiling-based targeting of pathogenic T cells with ustekinumab in ANCA-associated glomerulonephritis.Nature communications · 2024Article
- Cathepsin C inhibition reduces neutrophil serine protease activity and improves activated neutrophil-mediated disorders.Nature communications · 2024Article
- Review
- Female With Hypertensive Emergency Later Found to Have ANCA-Associated Vasculitis: A Case Report.Cureus · 2024Article
- A Refractory Case of Rapidly Progressive Glomerulonephritis Due to Microscopic Polyangiitis.Cureus · 2024Article
- Serum calprotectin and renal function decline in ANCA-associated vasculitides: a post hoc analysis of MAINRITSAN trial.RMD open · 2023Article
- Article
- New Insights into Pathogenesis and Treatment of ANCA-Associated Vasculitis: Autoantibodies and Beyond.Antibodies (Basel, Switzerland) · 2023Review
- A Case of Microscopic Polyangiitis Complicated by Mucormycosis: A Dangerous Balancing Act.Cureus · 2023Article
- Avacopan: First Approval.Drugs · 2022Review
Corrections and comments
- Comment on
- Comment on
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
34042399What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.